nodes	percent_of_prediction	percent_of_DWPC	metapath
Lithium—GSK3B—embryo—testicular cancer	0.0253	0.0911	CbGeAlD
Lithium—IMPA2—seminal vesicle—testicular cancer	0.0242	0.0872	CbGeAlD
Lithium—IMPA1—gonad—testicular cancer	0.0233	0.084	CbGeAlD
Lithium—GSK3A—seminal vesicle—testicular cancer	0.0206	0.0744	CbGeAlD
Lithium—IMPA1—female gonad—testicular cancer	0.0189	0.0683	CbGeAlD
Lithium—GSK3B—gonad—testicular cancer	0.0171	0.0619	CbGeAlD
Lithium—IMPA1—testis—testicular cancer	0.0168	0.0606	CbGeAlD
Lithium—IMPA2—Teniposide—Etoposide—testicular cancer	0.015	1	CbGdCrCtD
Lithium—GSK3A—gonad—testicular cancer	0.0149	0.0538	CbGeAlD
Lithium—GRIA3—testis—testicular cancer	0.0143	0.0515	CbGeAlD
Lithium—IMPA2—female gonad—testicular cancer	0.0142	0.0512	CbGeAlD
Lithium—GSK3B—female gonad—testicular cancer	0.0139	0.0503	CbGeAlD
Lithium—IMPA2—testis—testicular cancer	0.0126	0.0454	CbGeAlD
Lithium—GSK3B—testis—testicular cancer	0.0124	0.0446	CbGeAlD
Lithium—GSK3A—female gonad—testicular cancer	0.0121	0.0437	CbGeAlD
Lithium—GSK3A—testis—testicular cancer	0.0107	0.0388	CbGeAlD
Lithium—IMPA2—lymph node—testicular cancer	0.00913	0.0329	CbGeAlD
Lithium—GSK3B—lymph node—testicular cancer	0.00896	0.0323	CbGeAlD
Lithium—IMPA1—Integrated Breast Cancer Pathway—STK11—testicular cancer	0.00786	0.0205	CbGpPWpGaD
Lithium—GSK3A—lymph node—testicular cancer	0.00779	0.0281	CbGeAlD
Lithium—GSK3A—B Cell Receptor Signaling Pathway—BCL10—testicular cancer	0.00647	0.0169	CbGpPWpGaD
Lithium—GSK3B—LKB1 signaling events—STK11—testicular cancer	0.00597	0.0156	CbGpPWpGaD
Lithium—GSK3B—Signaling events mediated by Stem cell factor receptor (c-Kit)—KITLG—testicular cancer	0.00482	0.0126	CbGpPWpGaD
Lithium—GSK3B—B Cell Receptor Signaling Pathway—BCL10—testicular cancer	0.00478	0.0125	CbGpPWpGaD
Lithium—GSK3A—FOXM1 transcription factor network—MMP2—testicular cancer	0.00461	0.012	CbGpPWpGaD
Lithium—GSK3B—Cell Cycle—MAD1L1—testicular cancer	0.00432	0.0113	CbGpPWpGaD
Lithium—GSK3A—Constitutive PI3K/AKT Signaling in Cancer—KITLG—testicular cancer	0.0043	0.0112	CbGpPWpGaD
Lithium—GSK3A—Downstream signaling events of B Cell Receptor (BCR)—BCL10—testicular cancer	0.00419	0.0109	CbGpPWpGaD
Lithium—GSK3A—Fc epsilon receptor (FCERI) signaling—BCL10—testicular cancer	0.004	0.0104	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—PRDM14—testicular cancer	0.00394	0.0103	CbGpPWpGaD
Lithium—GSK3A—PI-3K cascade—KITLG—testicular cancer	0.00387	0.0101	CbGpPWpGaD
Lithium—GSK3A—PI3K/AKT activation—KITLG—testicular cancer	0.00378	0.00986	CbGpPWpGaD
Lithium—GSK3A—GAB1 signalosome—KITLG—testicular cancer	0.00375	0.00978	CbGpPWpGaD
Lithium—GSK3A—B Cell Activation—BCL10—testicular cancer	0.0037	0.00966	CbGpPWpGaD
Lithium—GSK3A—Role of LAT2/NTAL/LAB on calcium mobilization—KITLG—testicular cancer	0.00366	0.00956	CbGpPWpGaD
Lithium—GSK3A—Integrated Pancreatic Cancer Pathway—HPGDS—testicular cancer	0.00338	0.00881	CbGpPWpGaD
Lithium—GSK3B—Signaling events mediated by Stem cell factor receptor (c-Kit)—KIT—testicular cancer	0.00329	0.00859	CbGpPWpGaD
Lithium—GSK3A—Constitutive PI3K/AKT Signaling in Cancer—FGFR3—testicular cancer	0.00319	0.00833	CbGpPWpGaD
Lithium—GSK3B—Cardiac Progenitor Differentiation—KIT—testicular cancer	0.00319	0.00833	CbGpPWpGaD
Lithium—GSK3B—Constitutive PI3K/AKT Signaling in Cancer—KITLG—testicular cancer	0.00317	0.00828	CbGpPWpGaD
Lithium—GSK3B—Downstream signaling events of B Cell Receptor (BCR)—BCL10—testicular cancer	0.0031	0.00808	CbGpPWpGaD
Lithium—GSK3A—Integrated Breast Cancer Pathway—STK11—testicular cancer	0.00296	0.00772	CbGpPWpGaD
Lithium—GSK3B—Fc epsilon receptor (FCERI) signaling—BCL10—testicular cancer	0.00296	0.00771	CbGpPWpGaD
Lithium—GSK3A—Constitutive PI3K/AKT Signaling in Cancer—KIT—testicular cancer	0.00293	0.00765	CbGpPWpGaD
Lithium—GSK3A—Signaling by SCF-KIT—KITLG—testicular cancer	0.00289	0.00755	CbGpPWpGaD
Lithium—GSK3A—PI-3K cascade—FGFR3—testicular cancer	0.00288	0.00751	CbGpPWpGaD
Lithium—GSK3B—PI-3K cascade—KITLG—testicular cancer	0.00286	0.00746	CbGpPWpGaD
Lithium—GSK3A—PI3K/AKT activation—FGFR3—testicular cancer	0.00281	0.00733	CbGpPWpGaD
Lithium—GSK3B—PI3K/AKT activation—KITLG—testicular cancer	0.00279	0.00728	CbGpPWpGaD
Lithium—GSK3A—GAB1 signalosome—FGFR3—testicular cancer	0.00279	0.00727	CbGpPWpGaD
Lithium—GSK3B—GAB1 signalosome—KITLG—testicular cancer	0.00277	0.00723	CbGpPWpGaD
Lithium—GSK3B—Cell Cycle—KITLG—testicular cancer	0.00277	0.00723	CbGpPWpGaD
Lithium—GSK3A—Downstream signaling of activated FGFR—KITLG—testicular cancer	0.00277	0.00722	CbGpPWpGaD
Lithium—GSK3B—B Cell Activation—BCL10—testicular cancer	0.00273	0.00714	CbGpPWpGaD
Lithium—GSK3A—Signaling by ERBB4—KITLG—testicular cancer	0.00272	0.00711	CbGpPWpGaD
Lithium—GSK3A—Role of LAT2/NTAL/LAB on calcium mobilization—FGFR3—testicular cancer	0.00272	0.0071	CbGpPWpGaD
Lithium—GSK3B—Role of LAT2/NTAL/LAB on calcium mobilization—KITLG—testicular cancer	0.00271	0.00706	CbGpPWpGaD
Lithium—GSK3A—PI-3K cascade—KIT—testicular cancer	0.00264	0.00689	CbGpPWpGaD
Lithium—GSK3A—Downstream signal transduction—KITLG—testicular cancer	0.0026	0.00679	CbGpPWpGaD
Lithium—GSK3A—Signaling by FGFR—KITLG—testicular cancer	0.00259	0.00676	CbGpPWpGaD
Lithium—GSK3A—PI3K/AKT activation—KIT—testicular cancer	0.00258	0.00673	CbGpPWpGaD
Lithium—GSK3A—Signaling by ERBB2—KITLG—testicular cancer	0.00258	0.00672	CbGpPWpGaD
Lithium—GSK3A—DAP12 signaling—KITLG—testicular cancer	0.00256	0.00669	CbGpPWpGaD
Lithium—GSK3A—GAB1 signalosome—KIT—testicular cancer	0.00256	0.00667	CbGpPWpGaD
Lithium—GSK3A—Downstream signaling events of B Cell Receptor (BCR)—KITLG—testicular cancer	0.00253	0.00659	CbGpPWpGaD
Lithium—GSK3A—Role of LAT2/NTAL/LAB on calcium mobilization—KIT—testicular cancer	0.0025	0.00652	CbGpPWpGaD
Lithium—GSK3A—Integrated Pancreatic Cancer Pathway—STK11—testicular cancer	0.00245	0.0064	CbGpPWpGaD
Lithium—GSK3B—LPA receptor mediated events—MMP2—testicular cancer	0.00243	0.00634	CbGpPWpGaD
Lithium—GSK3A—Signaling by FGFR in disease—KITLG—testicular cancer	0.00241	0.00629	CbGpPWpGaD
Lithium—GSK3A—DAP12 interactions—KITLG—testicular cancer	0.00241	0.00629	CbGpPWpGaD
Lithium—GSK3A—Fc epsilon receptor (FCERI) signaling—KITLG—testicular cancer	0.00241	0.00629	CbGpPWpGaD
Lithium—GSK3A—Signaling by EGFR—KITLG—testicular cancer	0.00239	0.00624	CbGpPWpGaD
Lithium—GSK3A—Signaling by EGFR in Cancer—KITLG—testicular cancer	0.00237	0.00618	CbGpPWpGaD
Lithium—GSK3B—Constitutive PI3K/AKT Signaling in Cancer—FGFR3—testicular cancer	0.00236	0.00616	CbGpPWpGaD
Lithium—GSK3A—Signaling by PDGF—KITLG—testicular cancer	0.00236	0.00615	CbGpPWpGaD
Lithium—GSK3A—B Cell Activation—KITLG—testicular cancer	0.00223	0.00582	CbGpPWpGaD
Lithium—GSK3B—Constitutive PI3K/AKT Signaling in Cancer—KIT—testicular cancer	0.00217	0.00565	CbGpPWpGaD
Lithium—GSK3A—Signaling by SCF-KIT—FGFR3—testicular cancer	0.00215	0.00561	CbGpPWpGaD
Lithium—GSK3B—Signaling by SCF-KIT—KITLG—testicular cancer	0.00214	0.00558	CbGpPWpGaD
Lithium—GSK3A—NGF signalling via TRKA from the plasma membrane—KITLG—testicular cancer	0.00214	0.00557	CbGpPWpGaD
Lithium—GSK3B—PI-3K cascade—FGFR3—testicular cancer	0.00213	0.00555	CbGpPWpGaD
Lithium—GSK3B—PI3K/AKT activation—FGFR3—testicular cancer	0.00207	0.00541	CbGpPWpGaD
Lithium—GSK3B—Neural Crest Differentiation—FGFR3—testicular cancer	0.00207	0.00541	CbGpPWpGaD
Lithium—GSK3B—GAB1 signalosome—FGFR3—testicular cancer	0.00206	0.00537	CbGpPWpGaD
Lithium—GSK3A—Downstream signaling of activated FGFR—FGFR3—testicular cancer	0.00206	0.00537	CbGpPWpGaD
Lithium—GSK3B—Downstream signaling of activated FGFR—KITLG—testicular cancer	0.00205	0.00534	CbGpPWpGaD
Lithium—GSK3A—Signaling by ERBB4—FGFR3—testicular cancer	0.00202	0.00528	CbGpPWpGaD
Lithium—GSK3B—Signaling by ERBB4—KITLG—testicular cancer	0.00201	0.00525	CbGpPWpGaD
Lithium—GSK3B—Role of LAT2/NTAL/LAB on calcium mobilization—FGFR3—testicular cancer	0.00201	0.00525	CbGpPWpGaD
Lithium—GSK3A—Signaling by SCF-KIT—KIT—testicular cancer	0.00197	0.00515	CbGpPWpGaD
Lithium—GSK3B—PI-3K cascade—KIT—testicular cancer	0.00195	0.00509	CbGpPWpGaD
Lithium—GSK3A—Downstream signal transduction—FGFR3—testicular cancer	0.00193	0.00505	CbGpPWpGaD
Lithium—GSK3A—Signaling by FGFR—FGFR3—testicular cancer	0.00192	0.00502	CbGpPWpGaD
Lithium—GSK3B—Downstream signal transduction—KITLG—testicular cancer	0.00192	0.00502	CbGpPWpGaD
Lithium—GSK3A—Signaling by ERBB2—FGFR3—testicular cancer	0.00191	0.005	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR—KITLG—testicular cancer	0.00191	0.00499	CbGpPWpGaD
Lithium—GSK3A—DAP12 signaling—FGFR3—testicular cancer	0.00191	0.00497	CbGpPWpGaD
Lithium—GSK3B—PI3K/AKT activation—KIT—testicular cancer	0.0019	0.00497	CbGpPWpGaD
Lithium—GSK3B—Signaling by ERBB2—KITLG—testicular cancer	0.0019	0.00497	CbGpPWpGaD
Lithium—GSK3B—DAP12 signaling—KITLG—testicular cancer	0.00189	0.00494	CbGpPWpGaD
Lithium—GSK3B—GAB1 signalosome—KIT—testicular cancer	0.00189	0.00493	CbGpPWpGaD
Lithium—GSK3A—Downstream signaling of activated FGFR—KIT—testicular cancer	0.00189	0.00493	CbGpPWpGaD
Lithium—GSK3A—Downstream signaling events of B Cell Receptor (BCR)—FGFR3—testicular cancer	0.00188	0.0049	CbGpPWpGaD
Lithium—IMPA2—Metabolism—HPGDS—testicular cancer	0.00187	0.00488	CbGpPWpGaD
Lithium—GSK3B—Downstream signaling events of B Cell Receptor (BCR)—KITLG—testicular cancer	0.00187	0.00487	CbGpPWpGaD
Lithium—GSK3A—Signaling by ERBB4—KIT—testicular cancer	0.00186	0.00485	CbGpPWpGaD
Lithium—GSK3B—Role of LAT2/NTAL/LAB on calcium mobilization—KIT—testicular cancer	0.00185	0.00482	CbGpPWpGaD
Lithium—GSK3A—Fc epsilon receptor (FCERI) signaling—FGFR3—testicular cancer	0.00179	0.00468	CbGpPWpGaD
Lithium—GSK3A—Signaling by FGFR in disease—FGFR3—testicular cancer	0.00179	0.00468	CbGpPWpGaD
Lithium—GSK3A—DAP12 interactions—FGFR3—testicular cancer	0.00179	0.00468	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR in disease—KITLG—testicular cancer	0.00178	0.00465	CbGpPWpGaD
Lithium—GSK3B—DAP12 interactions—KITLG—testicular cancer	0.00178	0.00465	CbGpPWpGaD
Lithium—GSK3B—Fc epsilon receptor (FCERI) signaling—KITLG—testicular cancer	0.00178	0.00465	CbGpPWpGaD
Lithium—GSK3A—Signaling by EGFR—FGFR3—testicular cancer	0.00178	0.00464	CbGpPWpGaD
Lithium—GSK3A—Downstream signal transduction—KIT—testicular cancer	0.00178	0.00463	CbGpPWpGaD
Lithium—GSK3A—Signaling by FGFR—KIT—testicular cancer	0.00177	0.00461	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR—KITLG—testicular cancer	0.00177	0.00461	CbGpPWpGaD
Lithium—GSK3A—Signaling by EGFR in Cancer—FGFR3—testicular cancer	0.00176	0.00459	CbGpPWpGaD
Lithium—GSK3A—Signaling by ERBB2—KIT—testicular cancer	0.00176	0.00459	CbGpPWpGaD
Lithium—GSK3A—Signaling by PDGF—FGFR3—testicular cancer	0.00175	0.00457	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR in Cancer—KITLG—testicular cancer	0.00175	0.00457	CbGpPWpGaD
Lithium—GSK3A—DAP12 signaling—KIT—testicular cancer	0.00175	0.00456	CbGpPWpGaD
Lithium—GSK3B—Signaling by PDGF—KITLG—testicular cancer	0.00174	0.00455	CbGpPWpGaD
Lithium—GSK3A—Downstream signaling events of B Cell Receptor (BCR)—KIT—testicular cancer	0.00172	0.0045	CbGpPWpGaD
Lithium—IMPA1—Metabolism—HPGDS—testicular cancer	0.00167	0.00435	CbGpPWpGaD
Lithium—GSK3A—B Cell Activation—FGFR3—testicular cancer	0.00166	0.00433	CbGpPWpGaD
Lithium—GSK3B—B Cell Activation—KITLG—testicular cancer	0.00165	0.0043	CbGpPWpGaD
Lithium—GSK3A—DAP12 interactions—KIT—testicular cancer	0.00165	0.00429	CbGpPWpGaD
Lithium—GSK3A—Fc epsilon receptor (FCERI) signaling—KIT—testicular cancer	0.00165	0.00429	CbGpPWpGaD
Lithium—GSK3A—Signaling by FGFR in disease—KIT—testicular cancer	0.00165	0.00429	CbGpPWpGaD
Lithium—GSK3A—Signaling by NGF—KITLG—testicular cancer	0.00164	0.00429	CbGpPWpGaD
Lithium—GSK3B—TCF dependent signaling in response to WNT—H2AFZ—testicular cancer	0.00164	0.00428	CbGpPWpGaD
Lithium—GSK3A—Signaling by EGFR—KIT—testicular cancer	0.00163	0.00426	CbGpPWpGaD
Lithium—GSK3A—Signaling by EGFR in Cancer—KIT—testicular cancer	0.00162	0.00422	CbGpPWpGaD
Lithium—GSK3A—Signaling by PDGF—KIT—testicular cancer	0.00161	0.0042	CbGpPWpGaD
Lithium—GSK3B—Signaling by SCF-KIT—FGFR3—testicular cancer	0.00159	0.00415	CbGpPWpGaD
Lithium—GSK3B—RNF mutants show enhanced WNT signaling and proliferation—H2AFZ—testicular cancer	0.00159	0.00414	CbGpPWpGaD
Lithium—GSK3A—NGF signalling via TRKA from the plasma membrane—FGFR3—testicular cancer	0.00159	0.00414	CbGpPWpGaD
Lithium—GSK3B—NGF signalling via TRKA from the plasma membrane—KITLG—testicular cancer	0.00158	0.00412	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—BCL10—testicular cancer	0.00155	0.00406	CbGpPWpGaD
Lithium—GSK3A—B Cell Activation—KIT—testicular cancer	0.00152	0.00397	CbGpPWpGaD
Lithium—GSK3B—Downstream signaling of activated FGFR—FGFR3—testicular cancer	0.00152	0.00397	CbGpPWpGaD
Lithium—GSK3B—Signaling by ERBB4—FGFR3—testicular cancer	0.0015	0.0039	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—BCL10—testicular cancer	0.00149	0.00389	CbGpPWpGaD
Lithium—GSK3B—Signaling by WNT in cancer—H2AFZ—testicular cancer	0.00147	0.00385	CbGpPWpGaD
Lithium—GSK3B—Signaling by SCF-KIT—KIT—testicular cancer	0.00146	0.00381	CbGpPWpGaD
Lithium—GSK3A—NGF signalling via TRKA from the plasma membrane—KIT—testicular cancer	0.00146	0.0038	CbGpPWpGaD
Lithium—GSK3B—Downstream signal transduction—FGFR3—testicular cancer	0.00143	0.00373	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR—FGFR3—testicular cancer	0.00142	0.00371	CbGpPWpGaD
Lithium—GSK3B—Signaling by ERBB2—FGFR3—testicular cancer	0.00141	0.00369	CbGpPWpGaD
Lithium—GSK3B—DAP12 signaling—FGFR3—testicular cancer	0.00141	0.00367	CbGpPWpGaD
Lithium—GSK3B—Cellular responses to stress—H2AFZ—testicular cancer	0.00141	0.00367	CbGpPWpGaD
Lithium—GSK3B—Downstream signaling of activated FGFR—KIT—testicular cancer	0.0014	0.00364	CbGpPWpGaD
Lithium—GSK3B—Downstream signaling events of B Cell Receptor (BCR)—FGFR3—testicular cancer	0.00139	0.00362	CbGpPWpGaD
Lithium—GSK3B—Signaling by ERBB4—KIT—testicular cancer	0.00137	0.00358	CbGpPWpGaD
Lithium—IMPA2—Metabolism—STK11—testicular cancer	0.00136	0.00355	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR in disease—FGFR3—testicular cancer	0.00132	0.00346	CbGpPWpGaD
Lithium—GSK3B—DAP12 interactions—FGFR3—testicular cancer	0.00132	0.00346	CbGpPWpGaD
Lithium—GSK3B—Fc epsilon receptor (FCERI) signaling—FGFR3—testicular cancer	0.00132	0.00346	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR—FGFR3—testicular cancer	0.00131	0.00343	CbGpPWpGaD
Lithium—GSK3B—Downstream signal transduction—KIT—testicular cancer	0.00131	0.00342	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR—KIT—testicular cancer	0.00131	0.00341	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR in Cancer—FGFR3—testicular cancer	0.0013	0.00339	CbGpPWpGaD
Lithium—GSK3B—Signaling by ERBB2—KIT—testicular cancer	0.0013	0.00339	CbGpPWpGaD
Lithium—GSK3B—Signaling by PDGF—FGFR3—testicular cancer	0.0013	0.00338	CbGpPWpGaD
Lithium—GSK3B—DAP12 signaling—KIT—testicular cancer	0.00129	0.00337	CbGpPWpGaD
Lithium—GSK3B—Downstream signaling events of B Cell Receptor (BCR)—KIT—testicular cancer	0.00127	0.00332	CbGpPWpGaD
Lithium—GSK3B—B Cell Activation—FGFR3—testicular cancer	0.00123	0.0032	CbGpPWpGaD
Lithium—GSK3A—Signaling by NGF—FGFR3—testicular cancer	0.00122	0.00319	CbGpPWpGaD
Lithium—GSK3B—DAP12 interactions—KIT—testicular cancer	0.00122	0.00317	CbGpPWpGaD
Lithium—GSK3B—Fc epsilon receptor (FCERI) signaling—KIT—testicular cancer	0.00122	0.00317	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR in disease—KIT—testicular cancer	0.00122	0.00317	CbGpPWpGaD
Lithium—GSK3B—Signaling by Wnt—H2AFZ—testicular cancer	0.00122	0.00317	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—KITLG—testicular cancer	0.00121	0.00317	CbGpPWpGaD
Lithium—IMPA1—Metabolism—STK11—testicular cancer	0.00121	0.00316	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR—KIT—testicular cancer	0.00121	0.00314	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—INSL3—testicular cancer	0.0012	0.00313	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR in Cancer—KIT—testicular cancer	0.00119	0.00312	CbGpPWpGaD
Lithium—GSK3B—Signaling by PDGF—KIT—testicular cancer	0.00119	0.0031	CbGpPWpGaD
Lithium—GSK3B—NGF signalling via TRKA from the plasma membrane—FGFR3—testicular cancer	0.00117	0.00306	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—BCL10—testicular cancer	0.00115	0.003	CbGpPWpGaD
Lithium—GSK3B—B Cell Activation—KIT—testicular cancer	0.00113	0.00294	CbGpPWpGaD
Lithium—GSK3A—Signaling by NGF—KIT—testicular cancer	0.00112	0.00293	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—BCL10—testicular cancer	0.0011	0.00288	CbGpPWpGaD
Lithium—GSK3B—NGF signalling via TRKA from the plasma membrane—KIT—testicular cancer	0.00108	0.00281	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—KITLG—testicular cancer	0.000937	0.00245	CbGpPWpGaD
Lithium—GSK3A—Immune System—BCL10—testicular cancer	0.000905	0.00236	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—FGFR3—testicular cancer	0.000902	0.00235	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—KITLG—testicular cancer	0.0009	0.00235	CbGpPWpGaD
Lithium—Salivary hypersecretion—Epirubicin—testicular cancer	0.000895	0.00276	CcSEcCtD
Lithium—Decreased appetite—Vinblastine—testicular cancer	0.000894	0.00276	CcSEcCtD
Lithium—Urine output increased—Methotrexate—testicular cancer	0.00089	0.00274	CcSEcCtD
Lithium—Body temperature increased—Chlorambucil—testicular cancer	0.000888	0.00273	CcSEcCtD
Lithium—Abdominal pain—Chlorambucil—testicular cancer	0.000888	0.00273	CcSEcCtD
Lithium—GSK3B—Signaling Pathways—INSL3—testicular cancer	0.000885	0.00231	CbGpPWpGaD
Lithium—Confusional state—Bleomycin—testicular cancer	0.000876	0.0027	CcSEcCtD
Lithium—Oedema—Bleomycin—testicular cancer	0.000869	0.00268	CcSEcCtD
Lithium—Coordination abnormal—Doxorubicin—testicular cancer	0.000868	0.00267	CcSEcCtD
Lithium—Vision blurred—Ifosfamide—testicular cancer	0.000858	0.00264	CcSEcCtD
Lithium—Feeling abnormal—Vinblastine—testicular cancer	0.000848	0.00261	CcSEcCtD
Lithium—Coma—Epirubicin—testicular cancer	0.000842	0.00259	CcSEcCtD
Lithium—Gastrointestinal pain—Vinblastine—testicular cancer	0.000841	0.00259	CcSEcCtD
Lithium—Tinnitus—Cisplatin—testicular cancer	0.00084	0.00259	CcSEcCtD
Lithium—Agitation—Ifosfamide—testicular cancer	0.000836	0.00258	CcSEcCtD
Lithium—Discomfort—Dactinomycin—testicular cancer	0.000835	0.00257	CcSEcCtD
Lithium—Angioedema—Ifosfamide—testicular cancer	0.000832	0.00256	CcSEcCtD
Lithium—Anorexia—Bleomycin—testicular cancer	0.000828	0.00255	CcSEcCtD
Lithium—GSK3B—Signaling by NGF—KIT—testicular cancer	0.000828	0.00216	CbGpPWpGaD
Lithium—Salivary hypersecretion—Doxorubicin—testicular cancer	0.000828	0.00255	CcSEcCtD
Lithium—Vertigo—Ifosfamide—testicular cancer	0.000818	0.00252	CcSEcCtD
Lithium—Polyuria—Methotrexate—testicular cancer	0.000814	0.00251	CcSEcCtD
Lithium—Abdominal pain—Vinblastine—testicular cancer	0.000813	0.00251	CcSEcCtD
Lithium—Hypotension—Bleomycin—testicular cancer	0.000812	0.0025	CcSEcCtD
Lithium—Oedema—Dactinomycin—testicular cancer	0.00081	0.0025	CcSEcCtD
Lithium—Hypertonia—Epirubicin—testicular cancer	0.000808	0.00249	CcSEcCtD
Lithium—Asthenia—Chlorambucil—testicular cancer	0.000806	0.00248	CcSEcCtD
Lithium—Arrhythmia—Cisplatin—testicular cancer	0.000805	0.00248	CcSEcCtD
Lithium—Alopecia—Cisplatin—testicular cancer	0.000796	0.00245	CcSEcCtD
Lithium—Musculoskeletal discomfort—Bleomycin—testicular cancer	0.000792	0.00244	CcSEcCtD
Lithium—Convulsion—Ifosfamide—testicular cancer	0.000788	0.00243	CcSEcCtD
Lithium—Coma—Doxorubicin—testicular cancer	0.000779	0.0024	CcSEcCtD
Lithium—Arthralgia—Ifosfamide—testicular cancer	0.000775	0.00239	CcSEcCtD
Lithium—Flatulence—Cisplatin—testicular cancer	0.000773	0.00238	CcSEcCtD
Lithium—Anorexia—Dactinomycin—testicular cancer	0.000773	0.00238	CcSEcCtD
Lithium—Diarrhoea—Chlorambucil—testicular cancer	0.000768	0.00237	CcSEcCtD
Lithium—Discomfort—Ifosfamide—testicular cancer	0.000765	0.00236	CcSEcCtD
Lithium—Decreased appetite—Bleomycin—testicular cancer	0.000755	0.00233	CcSEcCtD
Lithium—Confusional state—Ifosfamide—testicular cancer	0.000749	0.00231	CcSEcCtD
Lithium—Hypertonia—Doxorubicin—testicular cancer	0.000747	0.0023	CcSEcCtD
Lithium—Oedema—Ifosfamide—testicular cancer	0.000743	0.00229	CcSEcCtD
Lithium—Vision blurred—Cisplatin—testicular cancer	0.000739	0.00228	CcSEcCtD
Lithium—Musculoskeletal discomfort—Dactinomycin—testicular cancer	0.000738	0.00227	CcSEcCtD
Lithium—Asthenia—Vinblastine—testicular cancer	0.000738	0.00227	CcSEcCtD
Lithium—Tremor—Cisplatin—testicular cancer	0.000735	0.00226	CcSEcCtD
Lithium—Alopecia—Etoposide—testicular cancer	0.00073	0.00225	CcSEcCtD
Lithium—Lethargy—Methotrexate—testicular cancer	0.00073	0.00225	CcSEcCtD
Lithium—Feeling abnormal—Bleomycin—testicular cancer	0.000716	0.00221	CcSEcCtD
Lithium—Vomiting—Chlorambucil—testicular cancer	0.000714	0.0022	CcSEcCtD
Lithium—Anorexia—Ifosfamide—testicular cancer	0.000708	0.00218	CcSEcCtD
Lithium—Decreased appetite—Dactinomycin—testicular cancer	0.000705	0.00217	CcSEcCtD
Lithium—Diarrhoea—Vinblastine—testicular cancer	0.000704	0.00217	CcSEcCtD
Lithium—Dysgeusia—Etoposide—testicular cancer	0.000704	0.00217	CcSEcCtD
Lithium—Fatigue—Dactinomycin—testicular cancer	0.000699	0.00215	CcSEcCtD
Lithium—GSK3A—Innate Immune System—FGFR3—testicular cancer	0.000696	0.00182	CbGpPWpGaD
Lithium—Hypotension—Ifosfamide—testicular cancer	0.000694	0.00214	CcSEcCtD
Lithium—GSK3B—Innate Immune System—KITLG—testicular cancer	0.000692	0.00181	CbGpPWpGaD
Lithium—Body temperature increased—Bleomycin—testicular cancer	0.000687	0.00212	CcSEcCtD
Lithium—Lethargy—Epirubicin—testicular cancer	0.000683	0.0021	CcSEcCtD
Lithium—Dizziness—Vinblastine—testicular cancer	0.00068	0.0021	CcSEcCtD
Lithium—Convulsion—Cisplatin—testicular cancer	0.00068	0.00209	CcSEcCtD
Lithium—Musculoskeletal discomfort—Ifosfamide—testicular cancer	0.000677	0.00208	CcSEcCtD
Lithium—Ataxia—Methotrexate—testicular cancer	0.000672	0.00207	CcSEcCtD
Lithium—GSK3B—Immune System—BCL10—testicular cancer	0.000669	0.00175	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—FGFR3—testicular cancer	0.000669	0.00175	CbGpPWpGaD
Lithium—Feeling abnormal—Dactinomycin—testicular cancer	0.000668	0.00206	CcSEcCtD
Lithium—Nausea—Chlorambucil—testicular cancer	0.000667	0.00205	CcSEcCtD
Lithium—GSK3B—Adaptive Immune System—KITLG—testicular cancer	0.000665	0.00174	CbGpPWpGaD
Lithium—GSK3B—Axon guidance—MMP2—testicular cancer	0.000664	0.00173	CbGpPWpGaD
Lithium—Gastrointestinal pain—Dactinomycin—testicular cancer	0.000663	0.00204	CcSEcCtD
Lithium—Somnolence—Ifosfamide—testicular cancer	0.00066	0.00203	CcSEcCtD
Lithium—Discomfort—Cisplatin—testicular cancer	0.00066	0.00203	CcSEcCtD
Lithium—Vomiting—Vinblastine—testicular cancer	0.000654	0.00202	CcSEcCtD
Lithium—Vertigo—Etoposide—testicular cancer	0.000646	0.00199	CcSEcCtD
Lithium—Decreased appetite—Ifosfamide—testicular cancer	0.000646	0.00199	CcSEcCtD
Lithium—Headache—Vinblastine—testicular cancer	0.000645	0.00199	CcSEcCtD
Lithium—Body temperature increased—Dactinomycin—testicular cancer	0.000641	0.00197	CcSEcCtD
Lithium—Abdominal pain—Dactinomycin—testicular cancer	0.000641	0.00197	CcSEcCtD
Lithium—Fatigue—Ifosfamide—testicular cancer	0.00064	0.00197	CcSEcCtD
Lithium—Oedema—Cisplatin—testicular cancer	0.00064	0.00197	CcSEcCtD
Lithium—GSK3A—Innate Immune System—KIT—testicular cancer	0.000639	0.00167	CbGpPWpGaD
Lithium—Loss of consciousness—Etoposide—testicular cancer	0.000632	0.00195	CcSEcCtD
Lithium—Lethargy—Doxorubicin—testicular cancer	0.000632	0.00195	CcSEcCtD
Lithium—Ataxia—Epirubicin—testicular cancer	0.000629	0.00194	CcSEcCtD
Lithium—Asthenia—Bleomycin—testicular cancer	0.000624	0.00192	CcSEcCtD
Lithium—Convulsion—Etoposide—testicular cancer	0.000623	0.00192	CcSEcCtD
Lithium—Dehydration—Epirubicin—testicular cancer	0.000622	0.00192	CcSEcCtD
Lithium—GSK3A—Adaptive Immune System—KIT—testicular cancer	0.000614	0.0016	CbGpPWpGaD
Lithium—Dry skin—Epirubicin—testicular cancer	0.000613	0.00189	CcSEcCtD
Lithium—Feeling abnormal—Ifosfamide—testicular cancer	0.000612	0.00189	CcSEcCtD
Lithium—Nausea—Vinblastine—testicular cancer	0.000611	0.00188	CcSEcCtD
Lithium—Anorexia—Cisplatin—testicular cancer	0.00061	0.00188	CcSEcCtD
Lithium—Gastrointestinal pain—Ifosfamide—testicular cancer	0.000607	0.00187	CcSEcCtD
Lithium—Discomfort—Etoposide—testicular cancer	0.000605	0.00186	CcSEcCtD
Lithium—Hypotension—Cisplatin—testicular cancer	0.000598	0.00184	CcSEcCtD
Lithium—Gastritis—Epirubicin—testicular cancer	0.000592	0.00182	CcSEcCtD
Lithium—Confusional state—Etoposide—testicular cancer	0.000591	0.00182	CcSEcCtD
Lithium—Muscular weakness—Epirubicin—testicular cancer	0.00059	0.00182	CcSEcCtD
Lithium—Abdominal pain—Ifosfamide—testicular cancer	0.000587	0.00181	CcSEcCtD
Lithium—Body temperature increased—Ifosfamide—testicular cancer	0.000587	0.00181	CcSEcCtD
Lithium—Musculoskeletal discomfort—Cisplatin—testicular cancer	0.000583	0.0018	CcSEcCtD
Lithium—Ataxia—Doxorubicin—testicular cancer	0.000582	0.00179	CcSEcCtD
Lithium—Asthenia—Dactinomycin—testicular cancer	0.000582	0.00179	CcSEcCtD
Lithium—Dehydration—Doxorubicin—testicular cancer	0.000576	0.00177	CcSEcCtD
Lithium—Erectile dysfunction—Methotrexate—testicular cancer	0.000569	0.00175	CcSEcCtD
Lithium—Dry skin—Doxorubicin—testicular cancer	0.000567	0.00175	CcSEcCtD
Lithium—Anorexia—Etoposide—testicular cancer	0.000559	0.00172	CcSEcCtD
Lithium—Decreased appetite—Cisplatin—testicular cancer	0.000557	0.00171	CcSEcCtD
Lithium—Diarrhoea—Dactinomycin—testicular cancer	0.000555	0.00171	CcSEcCtD
Lithium—Vomiting—Bleomycin—testicular cancer	0.000553	0.0017	CcSEcCtD
Lithium—Drowsiness—Methotrexate—testicular cancer	0.000551	0.0017	CcSEcCtD
Lithium—Hypotension—Etoposide—testicular cancer	0.000548	0.00169	CcSEcCtD
Lithium—Rash—Bleomycin—testicular cancer	0.000548	0.00169	CcSEcCtD
Lithium—Gastritis—Doxorubicin—testicular cancer	0.000548	0.00169	CcSEcCtD
Lithium—GSK3A—Disease—H2AFZ—testicular cancer	0.000548	0.00143	CbGpPWpGaD
Lithium—Dermatitis—Bleomycin—testicular cancer	0.000547	0.00169	CcSEcCtD
Lithium—Muscular weakness—Doxorubicin—testicular cancer	0.000546	0.00168	CcSEcCtD
Lithium—GSK3A—Immune System—KITLG—testicular cancer	0.000546	0.00142	CbGpPWpGaD
Lithium—Asthenia—Ifosfamide—testicular cancer	0.000533	0.00164	CcSEcCtD
Lithium—Feeling abnormal—Cisplatin—testicular cancer	0.000528	0.00163	CcSEcCtD
Lithium—Weight increased—Epirubicin—testicular cancer	0.000526	0.00162	CcSEcCtD
Lithium—Weight decreased—Epirubicin—testicular cancer	0.000523	0.00161	CcSEcCtD
Lithium—Hyperglycaemia—Epirubicin—testicular cancer	0.000522	0.00161	CcSEcCtD
Lithium—Somnolence—Etoposide—testicular cancer	0.000521	0.00161	CcSEcCtD
Lithium—Nausea—Bleomycin—testicular cancer	0.000516	0.00159	CcSEcCtD
Lithium—Drowsiness—Epirubicin—testicular cancer	0.000516	0.00159	CcSEcCtD
Lithium—Vomiting—Dactinomycin—testicular cancer	0.000515	0.00159	CcSEcCtD
Lithium—GSK3B—Innate Immune System—FGFR3—testicular cancer	0.000515	0.00134	CbGpPWpGaD
Lithium—Rash—Dactinomycin—testicular cancer	0.000511	0.00157	CcSEcCtD
Lithium—Decreased appetite—Etoposide—testicular cancer	0.00051	0.00157	CcSEcCtD
Lithium—Diarrhoea—Ifosfamide—testicular cancer	0.000508	0.00157	CcSEcCtD
Lithium—Body temperature increased—Cisplatin—testicular cancer	0.000506	0.00156	CcSEcCtD
Lithium—Fatigue—Etoposide—testicular cancer	0.000506	0.00156	CcSEcCtD
Lithium—GSK3A—Disease—KITLG—testicular cancer	0.000504	0.00131	CbGpPWpGaD
Lithium—GSK3A—Metabolism of proteins—MMP2—testicular cancer	0.000495	0.00129	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—FGFR3—testicular cancer	0.000494	0.00129	CbGpPWpGaD
Lithium—Dizziness—Ifosfamide—testicular cancer	0.000491	0.00151	CcSEcCtD
Lithium—Weight increased—Doxorubicin—testicular cancer	0.000487	0.0015	CcSEcCtD
Lithium—Weight decreased—Doxorubicin—testicular cancer	0.000484	0.00149	CcSEcCtD
Lithium—Feeling abnormal—Etoposide—testicular cancer	0.000483	0.00149	CcSEcCtD
Lithium—Hyperglycaemia—Doxorubicin—testicular cancer	0.000483	0.00149	CcSEcCtD
Lithium—Nausea—Dactinomycin—testicular cancer	0.000481	0.00148	CcSEcCtD
Lithium—Gastrointestinal pain—Etoposide—testicular cancer	0.00048	0.00148	CcSEcCtD
Lithium—Drowsiness—Doxorubicin—testicular cancer	0.000477	0.00147	CcSEcCtD
Lithium—GSK3B—Developmental Biology—MMP2—testicular cancer	0.000474	0.00124	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—KIT—testicular cancer	0.000472	0.00123	CbGpPWpGaD
Lithium—Vomiting—Ifosfamide—testicular cancer	0.000472	0.00145	CcSEcCtD
Lithium—Bradycardia—Epirubicin—testicular cancer	0.000471	0.00145	CcSEcCtD
Lithium—Rash—Ifosfamide—testicular cancer	0.000468	0.00144	CcSEcCtD
Lithium—Dermatitis—Ifosfamide—testicular cancer	0.000468	0.00144	CcSEcCtD
Lithium—Body temperature increased—Etoposide—testicular cancer	0.000464	0.00143	CcSEcCtD
Lithium—Abdominal pain—Etoposide—testicular cancer	0.000464	0.00143	CcSEcCtD
Lithium—Tinnitus—Methotrexate—testicular cancer	0.000461	0.00142	CcSEcCtD
Lithium—Asthenia—Cisplatin—testicular cancer	0.000459	0.00142	CcSEcCtD
Lithium—GSK3B—Adaptive Immune System—KIT—testicular cancer	0.000454	0.00118	CbGpPWpGaD
Lithium—Nausea—Ifosfamide—testicular cancer	0.000441	0.00136	CcSEcCtD
Lithium—Diarrhoea—Cisplatin—testicular cancer	0.000438	0.00135	CcSEcCtD
Lithium—Alopecia—Methotrexate—testicular cancer	0.000437	0.00135	CcSEcCtD
Lithium—Bradycardia—Doxorubicin—testicular cancer	0.000436	0.00134	CcSEcCtD
Lithium—Tinnitus—Epirubicin—testicular cancer	0.000432	0.00133	CcSEcCtD
Lithium—Dysgeusia—Methotrexate—testicular cancer	0.000422	0.0013	CcSEcCtD
Lithium—Asthenia—Etoposide—testicular cancer	0.000421	0.0013	CcSEcCtD
Lithium—Arrhythmia—Epirubicin—testicular cancer	0.000413	0.00127	CcSEcCtD
Lithium—Alopecia—Epirubicin—testicular cancer	0.000409	0.00126	CcSEcCtD
Lithium—Vomiting—Cisplatin—testicular cancer	0.000407	0.00125	CcSEcCtD
Lithium—Vision blurred—Methotrexate—testicular cancer	0.000406	0.00125	CcSEcCtD
Lithium—GSK3A—Immune System—FGFR3—testicular cancer	0.000406	0.00106	CbGpPWpGaD
Lithium—GSK3B—Disease—H2AFZ—testicular cancer	0.000405	0.00106	CbGpPWpGaD
Lithium—Rash—Cisplatin—testicular cancer	0.000404	0.00124	CcSEcCtD
Lithium—Dermatitis—Cisplatin—testicular cancer	0.000403	0.00124	CcSEcCtD
Lithium—GSK3B—Immune System—KITLG—testicular cancer	0.000403	0.00105	CbGpPWpGaD
Lithium—Diarrhoea—Etoposide—testicular cancer	0.000401	0.00124	CcSEcCtD
Lithium—Tinnitus—Doxorubicin—testicular cancer	0.000399	0.00123	CcSEcCtD
Lithium—Flatulence—Epirubicin—testicular cancer	0.000397	0.00122	CcSEcCtD
Lithium—Dysgeusia—Epirubicin—testicular cancer	0.000395	0.00122	CcSEcCtD
Lithium—Dizziness—Etoposide—testicular cancer	0.000388	0.00119	CcSEcCtD
Lithium—Vertigo—Methotrexate—testicular cancer	0.000387	0.00119	CcSEcCtD
Lithium—GSK3A—Signaling Pathways—H2AFZ—testicular cancer	0.000384	0.001	CbGpPWpGaD
Lithium—Arrhythmia—Doxorubicin—testicular cancer	0.000383	0.00118	CcSEcCtD
Lithium—GSK3A—Signaling Pathways—STK11—testicular cancer	0.000381	0.000995	CbGpPWpGaD
Lithium—Nausea—Cisplatin—testicular cancer	0.00038	0.00117	CcSEcCtD
Lithium—Vision blurred—Epirubicin—testicular cancer	0.00038	0.00117	CcSEcCtD
Lithium—Alopecia—Doxorubicin—testicular cancer	0.000378	0.00117	CcSEcCtD
Lithium—GSK3A—Disease—FGFR3—testicular cancer	0.000374	0.000977	CbGpPWpGaD
Lithium—Convulsion—Methotrexate—testicular cancer	0.000373	0.00115	CcSEcCtD
Lithium—Vomiting—Etoposide—testicular cancer	0.000373	0.00115	CcSEcCtD
Lithium—GSK3A—Immune System—KIT—testicular cancer	0.000372	0.000972	CbGpPWpGaD
Lithium—GSK3B—Disease—KITLG—testicular cancer	0.000372	0.000972	CbGpPWpGaD
Lithium—Agitation—Epirubicin—testicular cancer	0.00037	0.00114	CcSEcCtD
Lithium—Rash—Etoposide—testicular cancer	0.00037	0.00114	CcSEcCtD
Lithium—Dermatitis—Etoposide—testicular cancer	0.00037	0.00114	CcSEcCtD
Lithium—Headache—Etoposide—testicular cancer	0.000367	0.00113	CcSEcCtD
Lithium—Flatulence—Doxorubicin—testicular cancer	0.000367	0.00113	CcSEcCtD
Lithium—Arthralgia—Methotrexate—testicular cancer	0.000367	0.00113	CcSEcCtD
Lithium—Dysgeusia—Doxorubicin—testicular cancer	0.000365	0.00112	CcSEcCtD
Lithium—Discomfort—Methotrexate—testicular cancer	0.000362	0.00112	CcSEcCtD
Lithium—Vertigo—Epirubicin—testicular cancer	0.000362	0.00112	CcSEcCtD
Lithium—Syncope—Epirubicin—testicular cancer	0.000361	0.00111	CcSEcCtD
Lithium—Confusional state—Methotrexate—testicular cancer	0.000354	0.00109	CcSEcCtD
Lithium—Loss of consciousness—Epirubicin—testicular cancer	0.000354	0.00109	CcSEcCtD
Lithium—GSK3A—Signaling Pathways—KITLG—testicular cancer	0.000353	0.000921	CbGpPWpGaD
Lithium—Vision blurred—Doxorubicin—testicular cancer	0.000351	0.00108	CcSEcCtD
Lithium—Convulsion—Epirubicin—testicular cancer	0.000349	0.00108	CcSEcCtD
Lithium—Nausea—Etoposide—testicular cancer	0.000348	0.00107	CcSEcCtD
Lithium—GSK3A—Disease—KIT—testicular cancer	0.000344	0.000897	CbGpPWpGaD
Lithium—Arthralgia—Epirubicin—testicular cancer	0.000343	0.00106	CcSEcCtD
Lithium—Agitation—Doxorubicin—testicular cancer	0.000343	0.00106	CcSEcCtD
Lithium—Discomfort—Epirubicin—testicular cancer	0.000339	0.00104	CcSEcCtD
Lithium—Dry mouth—Epirubicin—testicular cancer	0.000335	0.00103	CcSEcCtD
Lithium—Vertigo—Doxorubicin—testicular cancer	0.000335	0.00103	CcSEcCtD
Lithium—Anorexia—Methotrexate—testicular cancer	0.000335	0.00103	CcSEcCtD
Lithium—Syncope—Doxorubicin—testicular cancer	0.000334	0.00103	CcSEcCtD
Lithium—Confusional state—Epirubicin—testicular cancer	0.000332	0.00102	CcSEcCtD
Lithium—Oedema—Epirubicin—testicular cancer	0.000329	0.00101	CcSEcCtD
Lithium—Hypotension—Methotrexate—testicular cancer	0.000328	0.00101	CcSEcCtD
Lithium—Loss of consciousness—Doxorubicin—testicular cancer	0.000328	0.00101	CcSEcCtD
Lithium—Shock—Epirubicin—testicular cancer	0.000323	0.000996	CcSEcCtD
Lithium—Convulsion—Doxorubicin—testicular cancer	0.000323	0.000995	CcSEcCtD
Lithium—Musculoskeletal discomfort—Methotrexate—testicular cancer	0.00032	0.000986	CcSEcCtD
Lithium—Arthralgia—Doxorubicin—testicular cancer	0.000317	0.000978	CcSEcCtD
Lithium—Discomfort—Doxorubicin—testicular cancer	0.000314	0.000966	CcSEcCtD
Lithium—Anorexia—Epirubicin—testicular cancer	0.000313	0.000965	CcSEcCtD
Lithium—Somnolence—Methotrexate—testicular cancer	0.000312	0.000962	CcSEcCtD
Lithium—Dry mouth—Doxorubicin—testicular cancer	0.00031	0.000956	CcSEcCtD
Lithium—Dyspepsia—Methotrexate—testicular cancer	0.000309	0.000953	CcSEcCtD
Lithium—Hypotension—Epirubicin—testicular cancer	0.000307	0.000946	CcSEcCtD
Lithium—Confusional state—Doxorubicin—testicular cancer	0.000307	0.000945	CcSEcCtD
Lithium—Decreased appetite—Methotrexate—testicular cancer	0.000305	0.000941	CcSEcCtD
Lithium—Oedema—Doxorubicin—testicular cancer	0.000304	0.000937	CcSEcCtD
Lithium—Fatigue—Methotrexate—testicular cancer	0.000303	0.000933	CcSEcCtD
Lithium—GSK3B—Immune System—FGFR3—testicular cancer	0.0003	0.000782	CbGpPWpGaD
Lithium—Musculoskeletal discomfort—Epirubicin—testicular cancer	0.0003	0.000923	CcSEcCtD
Lithium—Shock—Doxorubicin—testicular cancer	0.000299	0.000922	CcSEcCtD
Lithium—Somnolence—Epirubicin—testicular cancer	0.000292	0.0009	CcSEcCtD
Lithium—Anorexia—Doxorubicin—testicular cancer	0.00029	0.000893	CcSEcCtD
Lithium—Feeling abnormal—Methotrexate—testicular cancer	0.00029	0.000892	CcSEcCtD
Lithium—Dyspepsia—Epirubicin—testicular cancer	0.000289	0.000892	CcSEcCtD
Lithium—Gastrointestinal pain—Methotrexate—testicular cancer	0.000287	0.000885	CcSEcCtD
Lithium—Decreased appetite—Epirubicin—testicular cancer	0.000286	0.00088	CcSEcCtD
Lithium—Hypotension—Doxorubicin—testicular cancer	0.000284	0.000876	CcSEcCtD
Lithium—Fatigue—Epirubicin—testicular cancer	0.000283	0.000873	CcSEcCtD
Lithium—GSK3B—Signaling Pathways—H2AFZ—testicular cancer	0.000283	0.00074	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—STK11—testicular cancer	0.000282	0.000735	CbGpPWpGaD
Lithium—Abdominal pain—Methotrexate—testicular cancer	0.000278	0.000856	CcSEcCtD
Lithium—Body temperature increased—Methotrexate—testicular cancer	0.000278	0.000856	CcSEcCtD
Lithium—Musculoskeletal discomfort—Doxorubicin—testicular cancer	0.000277	0.000854	CcSEcCtD
Lithium—GSK3B—Disease—FGFR3—testicular cancer	0.000277	0.000722	CbGpPWpGaD
Lithium—GSK3B—Immune System—KIT—testicular cancer	0.000275	0.000718	CbGpPWpGaD
Lithium—Feeling abnormal—Epirubicin—testicular cancer	0.000271	0.000835	CcSEcCtD
Lithium—Somnolence—Doxorubicin—testicular cancer	0.00027	0.000833	CcSEcCtD
Lithium—Gastrointestinal pain—Epirubicin—testicular cancer	0.000269	0.000828	CcSEcCtD
Lithium—Dyspepsia—Doxorubicin—testicular cancer	0.000268	0.000825	CcSEcCtD
Lithium—Decreased appetite—Doxorubicin—testicular cancer	0.000264	0.000815	CcSEcCtD
Lithium—Fatigue—Doxorubicin—testicular cancer	0.000262	0.000808	CcSEcCtD
Lithium—GSK3A—Signaling Pathways—FGFR3—testicular cancer	0.000262	0.000684	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—KITLG—testicular cancer	0.000261	0.00068	CbGpPWpGaD
Lithium—Body temperature increased—Epirubicin—testicular cancer	0.00026	0.000801	CcSEcCtD
Lithium—Abdominal pain—Epirubicin—testicular cancer	0.00026	0.000801	CcSEcCtD
Lithium—GSK3B—Disease—KIT—testicular cancer	0.000254	0.000663	CbGpPWpGaD
Lithium—Asthenia—Methotrexate—testicular cancer	0.000252	0.000777	CcSEcCtD
Lithium—Feeling abnormal—Doxorubicin—testicular cancer	0.000251	0.000772	CcSEcCtD
Lithium—Gastrointestinal pain—Doxorubicin—testicular cancer	0.000249	0.000766	CcSEcCtD
Lithium—GSK3A—Signaling Pathways—KIT—testicular cancer	0.000241	0.000628	CbGpPWpGaD
Lithium—Abdominal pain—Doxorubicin—testicular cancer	0.000241	0.000741	CcSEcCtD
Lithium—Body temperature increased—Doxorubicin—testicular cancer	0.000241	0.000741	CcSEcCtD
Lithium—Diarrhoea—Methotrexate—testicular cancer	0.00024	0.000741	CcSEcCtD
Lithium—Asthenia—Epirubicin—testicular cancer	0.000236	0.000727	CcSEcCtD
Lithium—Dizziness—Methotrexate—testicular cancer	0.000232	0.000716	CcSEcCtD
Lithium—Diarrhoea—Epirubicin—testicular cancer	0.000225	0.000693	CcSEcCtD
Lithium—Vomiting—Methotrexate—testicular cancer	0.000223	0.000688	CcSEcCtD
Lithium—Rash—Methotrexate—testicular cancer	0.000222	0.000682	CcSEcCtD
Lithium—Dermatitis—Methotrexate—testicular cancer	0.000221	0.000682	CcSEcCtD
Lithium—Headache—Methotrexate—testicular cancer	0.00022	0.000678	CcSEcCtD
Lithium—Asthenia—Doxorubicin—testicular cancer	0.000218	0.000672	CcSEcCtD
Lithium—Dizziness—Epirubicin—testicular cancer	0.000217	0.00067	CcSEcCtD
Lithium—Vomiting—Epirubicin—testicular cancer	0.000209	0.000644	CcSEcCtD
Lithium—Nausea—Methotrexate—testicular cancer	0.000209	0.000643	CcSEcCtD
Lithium—Diarrhoea—Doxorubicin—testicular cancer	0.000208	0.000641	CcSEcCtD
Lithium—Rash—Epirubicin—testicular cancer	0.000207	0.000639	CcSEcCtD
Lithium—Dermatitis—Epirubicin—testicular cancer	0.000207	0.000638	CcSEcCtD
Lithium—Headache—Epirubicin—testicular cancer	0.000206	0.000635	CcSEcCtD
Lithium—Dizziness—Doxorubicin—testicular cancer	0.000201	0.00062	CcSEcCtD
Lithium—Nausea—Epirubicin—testicular cancer	0.000195	0.000602	CcSEcCtD
Lithium—GSK3B—Signaling Pathways—FGFR3—testicular cancer	0.000194	0.000506	CbGpPWpGaD
Lithium—Vomiting—Doxorubicin—testicular cancer	0.000193	0.000596	CcSEcCtD
Lithium—Rash—Doxorubicin—testicular cancer	0.000192	0.000591	CcSEcCtD
Lithium—Dermatitis—Doxorubicin—testicular cancer	0.000192	0.00059	CcSEcCtD
Lithium—Headache—Doxorubicin—testicular cancer	0.000191	0.000587	CcSEcCtD
Lithium—Nausea—Doxorubicin—testicular cancer	0.000181	0.000557	CcSEcCtD
Lithium—GSK3B—Signaling Pathways—KIT—testicular cancer	0.000178	0.000464	CbGpPWpGaD
